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A B S T R A C T
Cestode parasites cause neglected diseases, such as echinococcosis and cysticercosis, which represent a sig-
nificant problem in human and animal health. Benzimidazoles and praziquantel are the only available drugs for
chemotherapy and it is therefore important to identify new alternative drugs against cestode parasites. Histone
deacetylases (HDACs) are validated drug targets for the treatment of cancer and other diseases, including ne-
glected diseases. However, knowledge of HDACs in cestodes is very scarce. In this work, we investigated cestode
HDACs as potential drug targets to develop new therapies against neglected diseases caused by cestodes. Here we
showed the full repertoire of HDAC coding genes in several members of the class Cestoda. Between 6 and 7 zinc-
dependent HDAC coding genes were identified in the genomes of species from Echinococcus, Taenia,
Mesocestoides and Hymenolepis genera. We classified them as Class I and II HDACs and analyzed their tran-
scriptional expression levels throughout developmental stages of Echinococcus spp. We confirmed for the first
time the complete HDAC8 nucleotide sequences from Echinococcus canadensis G7 and Mesocestoides corti.
Homology models for these proteins showed particular structural features which differentiate them from HDAC8
from Homo sapiens. Furthermore, we showed that Trichostatin A (TSA), a pan-HDAC inhibitor, decreases the
viability of M. corti, alters its tegument and morphology and produces an increment of the total amount of
acetylated proteins, including acetylated histone H4. These results suggest that HDAC from cestodes are func-
tional and might play important roles on survival and development. The particular structural features observed
in cestode HDAC8 proteins suggest that these enzymes could be selectively targeted. This report provides the
basis for further studies on cestode HDAC enzymes and for discovery of new HDAC inhibitors for the treatment of
neglected diseases caused by cestode parasites.
1. Introduction
The cestode parasites Echinococcus spp., Taenia solium and
Hymenolepis nana are the etiological agents of echinococcosis (or hy-
datid disease), taeniasis/cysticercosis and hymenolepiasis, respectively.
These diseases principally affect vulnerable populations of many
countries in which sanitation and hygiene are inadequate, producing
serious economic losses associated with lost wages, treatment costs and
livestock production (Budke et al., 2006). Echinococcosis and cysti-
cercosis are among the 17 Neglected Tropical Diseases prioritized by
the WHO (WHO, 2012). Benzimidazoles, such as mebendazole and al-
bendazole (ABZ), and praziquantel (PZQ) are the only
chemotherapeutic agents approved for treatment. These compounds are
not well tolerated by some patients (Horton, 1997; Kyung et al., 2011;
Lee et al., 2011). ALB is reported to be ineffective in ∼40% of cystic
echinococcosis cases (Gottstein et al., 2015; Hemphill et al., 2014;
Stojkovic et al., 2009). Furthermore, resistance to PZQ was also re-
ported for schistosomiasis (Chai, 2013). Considering the previously
mentioned scenario, the discovery of novel potential alternatives for
chemotherapy against cestode diseases is imperative.
Bioinformatic approaches and the use of genomic resources are
commonly employed in the discovery of novel therapeutic targets. In
this context, the recent sequencing of several cestode genomes by
various research teams and the 50 Helminth Genomes Initiative headed
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by the Wellcome Trust Sanger Institute (Coghlan et al., 2017), in ad-
dition to the development of specific parasitic databanks such as
WormBase ParaSite (Coghlan et al., 2017; Howe et al., 2016, 2017),
provide essential tools for the discovery of novel therapeutic targets
against Neglected Tropical Diseases.
The scarce availability of biological material is one of the principal
experimental limitations associated with the work on cestode parasites.
In this work, we used Mesocestoides corti as a validated cestode model
(Hemphill, 2010). The M. corti larval developmental stage (tetra-
thyridium) has a remarkable capacity of asexual reproduction in the
peritoneal cavity of mice and some other mammalian hosts, providing a
continuous availability of biological material. Also, it is easily cultured
and is regarded as non-infective for humans (Hrčková et al., 1998;
Thompson et al., 1982).
Cestode parasites have complex life cycles that involve two or more
hosts, undergoing metamorphic events that involve cell proliferation,
differentiation and death. This remarkable phenotypic plasticity in-
volves a complex system of control of gene expression that has been
associated with changes in chromatin structure in trematodes and tur-
bellarians (Geyer and Hoffmann, 2012; Robb and Alvarado, 2014).
Enzymes involved in epigenetic mechanisms, especially DNA methyla-
tion and histone modifications, have been widely studied as potential
drug targets for human diseases (Yao and Seto, 2011). Among these,
histone deacetylase (HDAC) enzymes remove acetyl groups from lysine
residues in histone tails and other cellular effectors, thus directly in-
fluencing the chromatin structure and thereby regulating gene tran-
scription as well as other cellular processes. HDACs are validated drug
targets for the treatment of cancer (Mottamal et al., 2015) and a variety
of other diseases including, in the last years, Neglected Tropical Dis-
eases caused by protozoan as well as helminth parasites, in particular
Schistosoma mansoni (Andrews et al., 2012; Chakrabarti et al., 2015).
HDACs have been classified into four groups, based on sequence and
structure similarity (Gregoretti et al., 2004; Seto and Yoshida, 2014).
Class I, II and IV HDACs comprise enzymes that share similar catalytic
domains, which includes ion zinc as cofactor. Class III HDACs, also
called sirtuins, comprises the enzymes related to yeast Sir2 that are
NAD+-dependent and phylogenetically unrelated to Class I, II and IV
HDACs (Gregoretti et al., 2004; Seto and Yoshida, 2014). Class I, II and
IV are classically so-called HDACs (hereafter termed HDACs). In Homo
sapiens, Class I HDAC comprises the proteins HDAC1, HDAC2, HDAC3
and HDAC8. Class II HDACs is composed by the proteins HDAC4,
HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 and is also subdivided
in two subclasses: Class IIa HDACs (HDAC 4/5/7/9) and Class IIb
HDACs (HDAC6 and 10), integrated by the indicated proteins (Gray and
Ekström, 2001; Seto and Yoshida, 2014). Several HDAC enzymes have
been reported and characterized in flatworms (Cabezas-Cruz et al.,
2014; Geyer and Hoffmann, 2012; Pierce et al., 2012). Upon treating
platyhelminths of the genus Schistosoma with HDAC inhibitors used in
cancer, promising results have been obtained (Chua et al., 2017). Pre-
vious work about HDACs in cestodes revealed the presence of the
human HDAC1 ortholog in Echinococcus multilocularis genome and its
wide expression pattern in the germinal layer of cyst wall (Koziol et al.,
2014). However, information about cestode HDACs is very scarce.
The aims of this work were to identify and characterize Class I and
Class II HDACs in Echinococcus spp.,Mesocestoides corti, Hymenolepis spp.
and Taenia spp. We also aimed at studying the effect of the pan-HDAC
inhibitor, Trichostatin A (TSA), on M. corti larval developmental stage.
The identification and characterization of HDAC enzymes will con-
tribute to an understanding of the molecular basis of development and
survival in cestodes. This work will aid in developing new therapies
against Neglected Tropical Diseases caused by cestodes.
2. Materials and methods
2.1. Parasite material
Echinococcus granulosus sensu lato protoscoleces (PSC) were obtained
from hepatic hydatid cysts of porcine origin, provided by abattoirs from
Buenos Aires province, Argentina. The livers used in this work were
from animals that were not specifically used for this study. The material
obtained was processed as part of the normal work of the abattoir and
was collected under consent from local authorities. Briefly, PSC ex-
traction was performed under sterile conditions by needle aspiration of
cysts and washed three times with PBS supplemented with levofloxacin
(20 μg/mL) to remove cyst wall debris. Parasite viability was de-
termined by eosin exclusion test. Only samples showing more than 95%
viability were used. Species and genotype determination were per-
formed by sequencing of a fragment of the mitochondrial cytochrome c
oxidase subunit 1 as previously described (Avila et al., 2017; Cucher
et al., 2013). The results of genotyping indicated that the PSC used in
this work were from Echinococcus canadensis G7.
M. corti larval developmental stage, TTy (tetrathyridium), were
maintained in the laboratory by alternate intraperitoneal infection of
adult Balb/c female mice (3 months old) and Wistar female rats (6
months old), as previously described (Markoski et al., 2003). Experi-
mental animals were bred and housed in a temperature-controlled light
cycle room with food and water ad libitum at the animal facilities of
Instituto de Investigaciones en Microbiología y Parasitología Médica
(IMPaM), Facultad de Medicina, Universidad de Buenos Aires (UBA)-
Consejo Nacional de Investigaciones Científicas y Tecnológicas (CON-
ICET), Buenos Aires, Argentina. Mice were sacrificed by cervical dis-
location and TTy were collected from peritoneal cavity using standard
aseptic techniques and washed three times with PBS with levofloxacin
(20 μg/mL). Finally, parasites were selected using monofilament
polyester meshes to a final size of 150 μm–250 μm. Three independent
biological replicates were used, each one corresponding to TTy ob-
tained from a different mouse.
Before being employed in experimental protocols, PSC and TTy
were incubated for 24 h in 5mL of modified RPMI medium with 10%
inactivated foetal bovine serum (RPMI medium without phenol red
(Sigma-Aldrich, U.S.A.), 2.4 g/L HEPES (Sigma-Aldrich, U.S.A.), 2.5 g/L
glucose (Britania, Argentina), 50 μg/mL gentamicin and 20 μg/mL le-
vofloxacin added) at 37 °C under 5% CO2 atmosphere.
2.2. Ethics statement
Experiments involving the use of experimental animals were carried
out according to protocols approved by the Comité Institucional para el
Cuidado y Uso de Animales de Laboratorio (CICUAL), Facultad de
Medicina, Universidad de Buenos Aires, Argentina (protocols “in vivo
passages of cestode parasites from Mesocestoides corti” number CD N
1127/2015 and 1229/2015). Cyst puncture was performed following
the approved protocol by the same institution (protocol “Hydatid cysts
puncture from natural infections” number CD N˚ 3723/2014).
2.3. Bioinformatic analyses
Cestode HDAC encoding genes were identified using canonical
amino acid sequences of human HDAC1-11 (see identifiers in Fig. 1) in
BLASTP searches against the WormBase ParaSite database (Howe et al.,
2016, 2017). Cestode genomes used in this work were selected ac-
cording to reported parameters of CEGMA (>90%) and N50
(> 4.5 Kb), Supplementary Table S1. Retrieved parasite sequences with
E-value< 0.00001 were used to perform reciprocal BLASTP searches
against the Homo sapiens proteome (https://www.uniprot.org/
proteomes/UP000005640). HDAC gene models were predicted using
Augustus (Stanke et al., 2006) when HDAC genes were found in-
complete or truncated or were not found. Augustus was trained for the
H.R. Vaca, et al. IJP: Drugs and Drug Resistance 9 (2019) 120–132
121
genus Echinococcus as was previously described in Maldonado et al.
(2017). Also, identified cestode HDACs were used to perform BLASTP
searches against the Schistosoma mansoni proteome in the WormBase
ParaSite (Berriman et al., 2009; Protasio et al., 2012).
In order to define HDAC classes, the phylogenetic analysis was
performed using cestode and human conserved HDAC catalytic domain
amino acid residues (Pfam: PF00850). HDAC catalytic domain se-
quences were aligned using ClustalW. The sequences were adjusted
with manual edition when necessary. The phylogenetic tree was in-
ferred using the Maximum Likelihood method based on the JTT matrix-
based model. The bootstrap consensus tree was inferred from 1000
replicates. The analysis involved 90 amino acid sequences. All positions
with less than 95% site coverage were eliminated. There were a total of
76 positions in the final dataset. Evolutionary analyses were conducted
in MEGA5 (Tamura et al., 2011). Some cestode HDAC genes showed
two HDAC catalytic domains (EgrHDAC6, EmuHDAC6,
HmN_000118500 and TsM_000886700) or three HDAC catalytic do-
mains (ECAN7_01724, HDID_0000742001, TASs00024g03791m00001,
TSAs00013g02847m00001). The apparent presence of three HDAC
catalytic domains could be due to the draft nature of the genome as-
semblies in these species. Since all these HDAC domains showed a
phylogenetic relationship with HDAC6 or HDAC10 from H. sapiens and
S. mansoni, we named them as HDAC6A, HDAC6B and HDAC6C. The
percentages of identity of HDAC catalytic domains amino acid se-
quences between the cestodes analyzed and H. sapiens or S. mansoni
were obtained by Clustal2.1 for each HDAC catalytic domain.
Fig. 1. Phylogenetic tree of HDACs from Homo sapiens, Schistosoma mansoni and cestode parasites. Phylogenetic tree of the amino acid sequences of the HDAC
catalytic domains among the following cestode parasites: Echinococcus canadensis G7 (Eca), Echinococcus granulosus sensu stricto G1 (Egr), Echinococcus multilocularis
(Emu), Hymenolepis diminuta (Hdi), Hymenolepis microstoma (HmN), Mesocestoides corti (Mco), Taenia asiatica (Tas), Taenia saginata (Tsa), Taenia solium (Tsm) and
Homo sapiens (Hsa) and Schistosoma mansoni (Smp). Gene IDs are shown in brackets. Phylogenetic tree was obtained using the Maximum Likelihood method based on
the JTT matrix-based model. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates are collapsed and the percentage of replicate
trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The analysis involved 90 amino acid
sequences. All positions with less than 95% site coverage were eliminated. There were a total of 79 positions in the final dataset. Phylogenetic analysis was conducted
in MEGA5.
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Table 1
Identity of cestode histone deacetylase enzymes.
Tapeworm species Gene IDa Size (aa) Closest ortholog
Homo sapiens Schistosoma mansoni
HDAC Class E-value % of Identity HDAC (Gene IDa, E-value and % of Identity)
Echinococcus EcaHDAC1b 491 HDAC 2 I 0.0 69 HDAC 1 (Smp_005210, 0.0, 76)
canadensis G7 ECANG7_06509 424 HDAC 3 I 0.0 69 HDAC 3 (Smp_093280, 0.0, 76)
ECANG7_02279c 406 HDAC 8 I 4.0e−86 39 HDAC 8 (Smp_0911990, 1.0e−126, 46)
ECANG7_04174 1182 HDAC 5 II 2.0e−53 39 HDAC 5 (Smp_069380, 2.0e−77, 47)
ECAN7_01724 2066 HDAC 6 II 1.0e−146 36 HDAC 6 (Smp_138770, 0.0, 43)
ECANG7_00442 1293 HDAC 7 II 1.0e−112 40 HDAC 4 (Smp_191310, 0.0, 45)
Echinococcus EgrG_001102300 516 HDAC 2 I 0.0 69 HDAC 1 (Smp_005210, 0.0, 76)
granulosus EgrG_001114800 418 HDAC 3 I 0.0 69 HDAC 3 (Smp_093280, 0.0, 78)
sensu stricto G1 EgrG_000103800 406 HDAC 8 I 4.0e−86 39 HDAC 8 (Smp_0911990, 1.0e−126, 46)
EgrG_000527350 1116 HDAC 5 II 2.0e−53 39 HDAC 5 (Smp_069380, 2.0e−77, 48)
EgrHDAC6b 1128 HDAC 6 II 1.0e−105 37 HDAC 6 (Smp_138770, 1.0e−178, 44)
EGR_01373 1282 HDAC 7 II 1.0e−115 41 HDAC 4 (Smp_191310, 0.0, 50)
EgrG_000970800 827 HDAC 10 II 5.0e−99 43 HDAC 6 (Smp_138770, 1.0e−106, 41)
Echinococcus EmuJ_001102300 555 HDAC 2 I 0.0 69 HDAC 1 (Smp_005210, 0.0, 76)
multilocularis EmuJ_001114800 412 HDAC 3 I 0.0 69 HDAC 3 (Smp_093280, 0.0, 78)
EmuJ_000103800 406 HDAC 8 I 4.0e−87 39 HDAC 8 (Smp_0911990, 1.0e−128, 46)
EmuJ_000527350 1116 HDAC 5 II 1.0e−53 39 HDAC 5 (Smp_069380, 1.0e−77, 48)
EmuHDAC6b 1128 HDAC 6 II 1.0e−139 34 HDAC 6 (Smp_138770, 1.0e−178, 44)
EmuJ_000831600 650 HDAC 7 II 1.0e−115 41 HDAC 4 (Smp_191310, 0.0, 51)
EmuJ_000970800 820 HDAC 10 II 1.0e−18 42 HDAC 6 (Smp_138770, 1.0e−105, 42)
Hymenolepis HDID_0000695401 497 HDAC 1 I 0.0 76 HDAC 1 (Smp_005210, 0.0, 78)
diminuta HdiHDAC3b 357 HDAC 3 I 0.0 70 HDAC 3 (Smp_093280, 0.0, 76)
HDID_0000705201 415 HDAC 8 I 4.0e−76 36 HDAC 8 (Smp_0911990, 1.0e−113, 42)
HDID_0000742001 1832 HDAC 6 II 1.0e−153 41 HDAC 6 (Smp_138770, 0.0, 47)
HDID_0000456601 1292 HDAC 7 II 1.0e−115 43 HDAC 4 (Smp_191310, 0.0, 49)
HDID_0000011501 1153 HDAC 9 II 2.0e−50 38 HDAC 5 (Smp_069380, 4.0e−70, 46)
Hymenolepis HmN_000018400 496 HDAC 1 I 0.0 75 HDAC 1 (Smp_005210, 0.0, 73)
microstoma HmN_000625300 415 HDAC 3 I 0.0 68 HDAC 3 (Smp_093280, 0.0, 78)
HmN_000022600 408 HDAC 8 I 1.0e−89 40 HDAC 8 (Smp_0911990, 1.0e−121, 45)
HmN_000847300 1286 HDAC 4 II 1.0e−114 42 HDAC 4 (Smp_191310, 0.0, 52)
HmN_000118500 884 HDAC 6 II 3.0e−68 38 HDAC 6 (Smp_138770, 4.0e−89, 37)
HmN_000055900 522 HDAC 7 II 1.0e−46 53 HDAC 5 (Smp_069380, 3.0e−62, 75)
HmN_000118400 798 HDAC 10 II 1.0e−95 41 HDAC 6 (Smp_138770, 4.0e−96, 42)
Mesocestoides MCOS_0000151801 522 HDAC 2 I 0.0 72 HDAC 1 (Smp_005210, 0.0, 77)
corti MCOS_0000264901 423 HDAC 3 I 0.0 65 HDAC 3 (Smp_093280, 0.0, 79)
McoHDAC8c 408 HDAC 8 I 6.0e−82 40 HDAC 8 (Smp_0911990, 1.0e−114, 46)
MCOS_0000628401 1310 HDAC 4 II 1.0e−120 44 HDAC 4 (Smp_191310, 0.0, 52)
MCOS_0000067101 1225 HDAC 9 II 1.0e−52 40 HDAC 5 (Smp_069380, 8.0e−76, 39)
MCOS_0000847101 523 HDAC 10 II 7.0e−76 41 HDAC 6 (Smp_138770, 4.0e−77, 40)
Taenia TASK_0000062801 502 HDAC 2 I 0.0 72 HDAC 1 (Smp_005210, 0.0, 75)
asiatica TASK_0000683201 445 HDAC 3 I 1.0e−175 59 HDAC 3 (Smp_093280, 0.0, 68)
TASs00042g05048m00001 732 HDAC 8 I 2.0e−74 40 HDAC 8 (Smp_0911990, 1.0e−103, 47)
TASK_0000507001 1323 HDAC 4 II 1.0e−109 40 HDAC 4 (Smp_191310, 0.0, 46)
TASK_0000489301 1141 HDAC 5 II 2.0e−54 38 HDAC 5 (Smp_069380, 6.0e−74, 48)
TASs00024g03791m00001 2126 HDAC 10 II 7.0e−75 38 HDAC 6 (Smp_138770, 5.0e−96, 37)
Taenia TSAs00040g05661m00001 502 HDAC 2 I 0.0 72 HDAC 1 (Smp_005210, 0.0, 75)
saginata TSAs00037g05353m00001 377 HDAC 3 I 1.0e−95 62 HDAC 3 (Smp_093280, 1.0e−106, 71)
TSAs00052g06532m00001 732 HDAC 8 I 2.0e−74 40 HDAC 8 (Smp_0911990, 1.0e−104, 47)
TSAs00025g04272m00001 1302 HDAC 4 II 1.0e−115 41 HDAC 4 (Smp_191310, 0.0, 48)
TSAs00074g07737m00001 1141 HDAC 5 II 5.0e−55 38 HDAC 5 (Smp_069380, 4.0e−74, 48)
TSAs00013g02847m00001 2163 HDAC 6 II 1.0e−136 37 HDAC 6 (Smp_138770, 0.0, 41)
Taenia TsM_000660000 502 HDAC 2 I 0.0 69 HDAC 1 (Smp_005210, 0.0, 75)
solium TsM_000728400 405 HDAC 3 I 1.0e−129 58 HDAC 3 (Smp_093280, 1.0e−159, 67)
TsM_000312400 447 HDAC 8 I 6.0e−73 40 HDAC 8 (Smp_0911990, 1.0e−106, 47)
TsM_000840000 556 HDAC 4 II 4.0e−88 42 HDAC 4 (Smp_191310, 1.0e−139, 49)
TsM_000886700 951 HDAC 6 II 1.0e−120 36 HDAC 6 (Smp_138770, 1.0e−174, 40)
TsM_000033200 1144 HDAC 7 II 2.0e−50 37 HDAC 5 (Smp_069380, 7.0e−72, 48)
TsM_000886600 816 HDAC 10 II 3.0e−78 41 HDAC 6 (Smp_138770, 9.0e−89, 44)
a Gene ID according to the genome annotation on WormBase Parasite.
b Genes predicted using Augustus gene predictor.
c Genes validated by cDNA cloning and sequencing.
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2.4. HDAC expression analyses
The transcriptional expression levels of HDAC genes (in RPKM, or
reads per kilobase million reads) were analyzed using available RNA-
seq data from Echinococcus granulosus sensu stricto (s. s.) G1 (Zheng
et al., 2013) and Echinococcus multilocularis (Huang et al., 2016). Ex-
pression level of each HDAC was compared among different develop-
mental stages. In E. granulosus s. s. G1, the analyzed developmental
stages were: protoscoleces (PSC), germinal and laminated layers (cyst
wall-CW), oncospheres (Onc) and adult. In E. multilocularis, the ana-
lyzed developmental stages were: oncospheres (Onc), activated onco-
spheres (Act Onc) and 4-week metacestodes miniature vesicles (4wCW).
In E. canadensis G7 and M. corti, expression levels of HDAC genes were
not analyzed since RNA-seq data are not available.
2.5. Echinococcus canadensis and Mesocestoides corti HDAC8 cloning,
sequencing and homology modeling
Full coding sequences (CDSs) of HDAC8 from M. corti TTy
(McoHDAC8) and E. canadensis G7 PSC (EcaHDAC8) were obtained as
follows: total RNA was extracted from parasite material using Trizol
(Life Technologies, U.S.A.) according to the manufacturer's instructions.
A total of 2 μg of RNA were treated with RNase-free DNase I (Thermo
Fisher Scientific, U.S.A.) and reverse transcribed using SuperScript III
Reverse Transcriptase (Thermo Fisher Scientific, U.S.A.) and Oligo
(dT)18 primer (Integrated DNA Technologies, U.S.A.). PCR amplifica-
tion was performed with KAPA High Fidelity DNA Polymerase
(Biosystem, U.S.A.) using gene specific primers for McoHDAC8: forward
(McoHDAC8-F: 5′-ATGCCTTCGCGAGTTGGCATTG-3′) and reverse
(McoHDAC8-R: 5-CTATGGACCCAGGCGATTGAACGA-3′) and
EcaHDAC8: forward (EcaHDAC8-F: 5′-ATGCCCTCTCCCGTTGGTA
TTG-3′) and reverse (EcaHDAC8-R: 5′-TTAAACGCGGTTAAAGGCA
CAA-3′). The primers were manually designed to obtain the complete
CDSs, based on the HDAC8 nucleotide sequences identified. Finally, A-
tails were added to PCR products that were cloned into the pCR2.1-
TOPO vector using TOPO® TA Cloning kit (Thermo Fisher Scientific,
U.S.A.) according to the manufacturer's recommendations. HDAC8
genes were sequenced in both directions using a 300 Applied
Biosystems Big Dye terminator kit (Applied Biosystems) on an ABI 377
automated DNA sequencer at Macrogen (Macrogen, South Korea), using
specific HDAC8 primers and M13 sequences integrated into the vector.
HDAC8 sequences were constructed using PhredPhrap program
(Gordon et al., 1998, 2001). Translation of nucleotide sequences to
amino acid sequences were performed using Translate tool from the
Bioinformatics Resource Portal ExPASy (https://web.expasy.org/
translate/). Nucleotide and amino acid sequences obtained are shown
in Supplementary Data S1 and S2.
The homology modeling of EcaHDAC8 and McoHDAC8 were per-
formed using the programs PHYRE2 (Kelley et al., 2015) and SWISS-
MODEL (Arnold et al., 2006; Benkert et al., 2008; Biasini et al., 2014).
Already crystallized structures from Homo sapiens HsaHDAC8, PDB ID:
1t64 (Somoza et al., 2004) and Schistosoma mansoni SmpHDAC8, PDB
ID: 4bz5 (Marek et al., 2013) were used as templates for the modeling.
The molecular visualization of models and figures generated in this
work were performed using the software PyMol version 2.0.4 (https://
pymol.org). All models obtained were validated calculating several
parameters such as: TMscore (https://zhanglab.ccmb.med.umich.edu/
TM-score/), RMSD (integrated in PyMol), ERRAT and Verify-3D
(http://servicesn.mbi.ucla.edu/SAVES/). Ramachandran plots were
produced using Rampage (http://mordred.bioc.cam.ac.uk/∼rapper/
rampage.php). Finally, structural comparisons among the designed
models and H. sapiens and S. masoni HDAC8 were performed to identify
conserved residues in the catalytic pocket and the residues involved in
the Zinc and TSA binding site.
Fig. 2. Comparison of HDAC catalytic domains amino acid residues. Percentage of identity of HDAC catalytic domains amino acid residues between the
following cestodes: Echinococcus canadensis G7 (Eca), Echinococcus granulosus sensu stricto G1 (Egr), Echinococcus multilocularis (Emu), Hymenolepis diminuta (Hdi),
Hymenolepis microstoma (HmN), Mesocestoides corti (Mco), Taenia asiatica (Tas), Taenia saginata (Tsa), Taenia solium (Tsm) and Homo sapiens (Hsa) or Schistosoma
mansoni (Smp). Each panel shows the percentage of identity for each HDAC gene. The values were taken from a percent identity matrix created by Clustal2.1.
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2.6. Effect of drug treatment on Mesocestoides corti viability
The stock solutions of TSA (Cell Signaling Technology, U.S.A.) and
PZQ were prepared in 100% DMSO at 200x of the maximum con-
centration to be used. In order to determine the effect of the pan-HDAC
inhibitor TSA on M. corti TTy viability, this compound was tested at
concentrations in the range from 1 μM to 20 μM. Also, concentrations of
PZQ from 1 μM to 20 μM were tested. Parasites pre-treated with ethanol
70% for 30min were used as positive control. All assays were per-
formed with equal amount of the vehicle (1% DMSO final concentra-
tion) and with its corresponding negative control (1% DMSO).
Previously, we had confirmed that 1% DMSO was not toxic for M. corti
TTy (Supplementary Fig. S1). The cultures were maintained at 37 °C
under 5% CO2 atmosphere for 6 days without change of culture
medium. Parasite viability on M. corti TTy was determined using Ala-
marBlue assay® (Thermo Fisher Scientific, U.S.A.) (Stadelmann et al.,
2016) and a motility assay with a worm tracker device (WMicrotracker
Designplus SRL, Argentina) (Simonetta and Golombek, 2007). In both
cases, parasites (20 TTy for AlamarBlue assay® and 5 TTy for motility
assay) were incubated in 200 μL of culture medium per well in U-shape
96-well microplates (Greiner Bio-One, Germany). The AlamarBlue
assay® was performed at 3 and 6 days after the addition of the corre-
sponding drugs. Briefly, 20 μL of AlamarBlue reagent were added per
well and incubated at 37 °C under 5% CO2 atmosphere during 24 h.
Assay plates were read at 570 nm and 600 nm in a Multiskan FC mi-
croplate photometer (Thermo Fisher Scientific, U.S.A.). The percentage
of reduction of AlamarBlue reagent was calculated for each assay and
compared with the control, according to the manufacturer's re-
commendations. The motility assay was performed with a worm tracker
device adapted to measure movement of M. corti TTy. The motility
index was calculated as previously described in Camicia et al. (2013,
2018).
One-way ANOVA test was used to analyze the effects of drugs on
parasitic viability measured by both assays. Significant differences
(P < 0.05) were determined by Dunnett's comparisons post-test. The
analyses were performed for three independent biological replicates,
each one in triplicate for the Alamar Blue assay and in quadruplicate for
the motility assay, comparing each drug and concentration with the
control.
In order to determine any possible morphological alterations,
parasite cultures were visualized with an inverted microscope coupled
to a digital video camera (Carl Zeiss, Germany).
2.7. Western blots
M. corti TTy were treated with TSA 20 μM, TSA 40 μM, PZQ 20 μM,
ABZ 20 μM and 1% DMSO. The stock solutions were prepared as pre-
viously described (see 2.6 section). Total protein extracts were obtained
from TTy after 3 and 6 days of incubation. Briefly, 50 μL of each
parasite pellet (100 TTy approximately) were resuspended in
Radioimmunoprecipitation assay buffer (RIPA buffer: 50mM Tris HCl
pH 8, 150mM NaCl, 5 mM EDTA pH 8, 0.5% sodium deoxycholate,
0.1% SDS, 1% Triton-X100) with 5mM sodium butyrate and 10 μL/mL
Protease Inhibitor Cocktail-P8340 (Sigma-Aldrich, U.S.A.), and dis-
rupted by sonication: 60% intensity, 6 times 30 s, with incubation in-
tervals on ice (Ultrasonic cell disruptor-Torbéo). Complete lysis was
verified by inverted microscope inspection. Following centrifugation at
12 000 g for 10min, supernatants were collected and protein con-
centration was determined by Bradford assay (Bio-Rad, U.S.A.)
(Bradford, 1976). The samples were conserved at −80 °C until use.
Protein extracts were analyzed by SDS-PAGE (He, 2011) and Western
blot (Burnette, 1981). Briefly, 25 μg of protein from each sample were
dissolved in 6X SDS-PAGE loading dye and denatured by heating at
98 °C for 5min. Protein separation was performed by 15% SDS-PAGE
mini-gel and transferred to nitrocellulose Amersham RPN203D mem-
branes (GE Healthcare, U.S.A.) by the semi-dry method (SEMI-PHOR
Bio-Rad, U.S.A.). The membranes were blocked with Tris-buffer saline,
0.1% Tween 20 (TBST) with 5% milk for 2 h at room temperature and
incubated overnight at 4 °C on a platform rocker with anti acetylated-
histone H4 rabbit polyclonal antibody directed to a KLH conjugated
peptide [AGGAcKGGAcKGMGAcKVGAAcKRHS-C] corresponding to
amino acids 2–19 of Tetrahymena histone H4 acetylated in all the lysine
residues at 1:2000 dilution (06–866 EMD Millipore, U.S.A.) or anti
acetylated-KLH conjugated rabbit polyclonal antibody (anti pan-
acetylated-protein) at 1:2000 dilution (ICP0380 Inmunechem, Canada).
After incubation, membranes were washed three times in TBST for
5min, incubated with anti-rabbit HRP-conjugated antibody at 1:3000
dilution (Sigma-Aldrich, U.S.A.) for 2 h at RT on a platform rocker and
washed twice in TBST for 5min and once in TBS for another 5min.
Antigen-antibody complexes on membranes were detected using ECL
detection reagent (Sigma-Aldrich, U.S.A.) as described (Mruk and
Cheng, 2011) and visualized by BioSpectrum 515 Imaging Systems
(UVP, Germany), according to the manufacturer's recommendations.
Densitometry analyses were carried out using ImageJ Version 1.49
software. Western blot signals of two independent biological replicates
were normalized with the total amount of proteins of the same sample
observed by Coomassie Blue staining in a 15% SDS-PAGE mini-gel
loaded with the same samples and run in parallel. The results were
expressed as the fold change in relative density compared to the vehicle
control (1% DMSO).
Fig. 3. Transcriptional expression levels of HDAC genes in parasites of
genus Echinococcus spp. HDAC transcriptional expression levels are shown as
RPKM (Reads Per Kilobase Million). (A) Comparative HDAC transcriptional
expression gene levels, determined by RNAseq, in several developmental stages
of Echinococcus granulosus sensu stricto G1: adult, oncospheres (Onc), cyst wall
(CW) and protoscoleces (PSC) (Zheng et al., 2013). (B) Comparative HDAC
transcriptional expression gene levels, determined by RNAseq, in several de-
velopmental stages of Echinococcus multilocularis: oncospheres (Onc), activated
oncospheres (Act Onc) and 4-week metacestodes miniature vesicles (4wCW)
(Huang et al., 2016).
H.R. Vaca, et al. IJP: Drugs and Drug Resistance 9 (2019) 120–132
125
3. Results
3.1. Class I and class II HDAC genes are present in cestode genomes
All HDAC genes found in cestode genomes are shown in Table 1.
Examination of the cestode genomes revealed the presence of seven
HDAC genes in E. granulosus sensu stricto (s. s.) G1, E. multilocularis,
Hymenolepis microstoma and Taenia solium; and six HDAC genes in the
draft genomes of E. canadensis G7, Hymenolepis diminuta, M. corti;
Taenia asiatica and Taenia saginata. Human and S. mansoni HDAC closest
orthologs to each cestode HDAC gene found are shown in Table 1. The
comparisons between the HDAC genes found in the two genomes
available from E. granulosus s. s. G1 and T. asiatica are shown in
Supplementary Tables S2 and S3, respectively.
In order to define the identity and determine evolutionary re-
lationships among cestode, human and S. mansoni HDACs, phylogenetic
analysis of conserved HDAC catalytic domains was carried out (Fig. 1).
We found that cestode HDACs from different species of the same genus
grouped together. Also, this analysis allowed us to classify cestode
HDACs into the two main classes, I and II. We found three members of
Class I HDAC in all cestodes analyzed; in particular, we identified only
one member of subclass HDAC1/2. We named these members as
HDAC1. We found three or four members of Class II HDAC in all ces-
todes analyzed; these members were named according to relationships
with S. mansoni HDAC orthologs (Fig. 1). We compared the level of
amino acid identity of cestode HDAC catalytic domains with human
HDAC catalytic domains since this analysis provides relevant informa-
tion to select the best potential cestode HDAC drug target (Fig. 2).
Cestode HDAC1 and HDAC3 showed the highest similarity to their
corresponding human orthologs with amino acid identities above 86%
and 64%, respectively. Cestode HDAC8 showed amino acid identities of
only about 45–48% with the human orthologs. Cestode HDACs 4/5/6/
10 showed amino acid identities with their human orthologs in the
range from 41% to 61% (Fig. 2). We also compared the level of identity
of amino acid sequences of HDAC catalytic domains previously reported
from S. mansoni with their corresponding orthologs found in cestodes.
Cestode HDAC1 and HDAC3 were the most similar to their corre-
sponding S. mansoni orthologs, with amino acid identities of up to 86%
Fig. 4. Comparative analysis of HDAC8 from Homo sapiens, Schistosoma mansoni, Echinococcus canadensis G7 and Mesocestoides corti. (A) Alignment of
amino acid sequences of HDAC8 from H. sapiens (HsaHDAC8), S. mansoni (SmpHDAC8), E. canadensis G7 (EcaHDAC8) and M. corti (McoHDAC8). Sequence simi-
larities are shown in green levels. Conserved residues indicated below the alignment are involved in coordinating the zinc ion (rhombus), catalysis and active site
formation (quadrate).(B) Superposition of native HsaHDAC8 (red; PDB 1T64; H. sapiens), SmpHDAC8 (purple; PDB 4BZ5; S. mansoni.) and models of EcaHDAC8
(blue; E. canadensis G7) and McoHDAC8 (green; M. corti) structures represented as ribbons. All HDAC8 enzymes adopted the canonical HDAC fold. The yellow sphere
represents the catalytic ion zinc (Zn). Close view of active sites of (C) HsaHDAC8, (D) SmpHDAC8, (E) EcaHDAC8 and (F) McoHDAC8. The residues involved in zinc
binding, catalysis and active site formation are shown as sticks. Residues are conserved in parasite HDAC8s, only L31 and M274 are replaced by serine and histidine,
respectively, EcaHDAC8 (S20; H286) and McoHDAC8 (S20; H286), as well as in SmpHDAC8 (S18; H292). (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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and 74%, respectively. The other cestode HDACs showed amino acid
identities with their S. mansoni orthologs in the range from 37 to 73%
(Fig. 2).
3.2. HDAC genes are expressed in different developmental stages of
Echinococcus spp
We analyzed transcriptional expression levels of HDAC genes for
several developmental stages in Echinococcus spp. (Fig. 3). All HDAC
genes are expressed in at least one developmental stage analyzed. In E.
granulosus s. s. G1, HDAC1 and HDAC6 were expressed in all develop-
mental stages analyzed, the levels of HDAC1 being higher than other
HDACs in adult, oncospheres and cyst wall developmental stages.
HDAC10 level was the highest HDAC level in protoscoleces. HDAC8
was only expressed in adult and cyst wall (Fig. 3A). In E. multilocularis,
all HDACs were expressed in all developmental stages analyzed, with
the only exception of HDAC5. HDAC1 levels were higher than other
HDACs in oncospheres and cyst wall developmental stages. HDAC8
showed an expression level superior to other HDACs in activated on-
cospheres developmental stage (Fig. 3B).
3.3. HDAC8 is a potential drug target in cestode parasites
We characterized HDAC8 from E. canadensis G7 andM. corti (Fig. 4).
We focused on the analysis of EcaHDAC8 and McoHDAC8, in order to
determine if these proteins share structural differences with HsaHDAC8
and structural similarities with SmpHDAC8, a validated drug target in
S. mansoni. The complete CDSs of HDAC8 from E. canadensis G7 and M.
corti were confirmed by cloning and sequencing. The alignment of the
complete CDSs of HDAC8 from H. sapiens, S. mansoni, E. canadensis G7
and M. corti is shown in Fig. 4A. The amino acid alignment showed that
E. canadensis G7 and M. corti HDAC8 domains displayed a general level
of conservation with HsaHDAC8. We found that EcaHDCA8 and
McoHDAC8 contained specific insertions, also present in SmpHDAC8,
which were not present in HsaHDAC8. We obtained the model struc-
tures of HDAC8 from E. canadensis G7 and M. corti. We performed
structural alignment of these model structures with the native
SmpHDAC8 and HsaHDAC8 (Fig. 4B). EcaHDAC8 and McoHDAC8
model structures adopted the canonical HDAC fold, forming a single α/
β domain in which several stranded parallel β-sheet were sandwiched
between α-helices. We showed that the important residues implicated
in the catalytic mechanism were highly conserved in EcaHDAC8 and
McoHDAC8. We represented as ribbon and sticks the closed-up views of
the active sites from HsaHDAC8 (Fig. 4C), SmpHDAC8 (Fig. 4D),
EcaHDAC8 (Fig. 4E) and McoHDAC8 (Fig. 4F). We found that only
leucine (L31) and methionine (M274) from HsaHDAC8 were replaced
by a serine and histidine residues in EcaHDAC8 (S20 and H286) and
Fig. 5. Amino acid residues surrounding the phenylalanine of HDAC8
from Homo sapiens, Schistosoma mansoni, Echinococcus canadensis G7 and
Mesocestoides corti. Structures of HDAC8 from H. sapiens PDB 1T64
(HsaHDAC8 F152), S. mansoni PDB 4BZ5 (SmpHDAC8 F151), E. canadensis
G7 (EcaHDAC8 F154) and M. corti (McoHDAC8 F154) are shown. The re-
placement of leucine in HsaHDAC8 (L31) by a smaller residue as serine in
SmpHDAC8 (S18), EcaHDAC8 (S20) and McoHDAC8 (S20), together with
several aromatic residues (“aromatic cage” is shown as mesh) in SmpHDAC8
(purple: F21, F104, Y110, W140 and Y153), EcaHDAC8 (blue: Y23, F107, Y113,
W143 and Y156) and McoHDAC8 (green: Y23, F107, Y113, W143 and Y156),
form a cavity behind the phenylalanine which can adopt a especial conforma-
tion know as “flipped-out”. Residues above mentioned are shown as sticks (red
from HsaHDAC8 and white from SmpHDAC8, EcaHDAC8 and McoHDAC8).
(For interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
Fig. 6. Residues involved in Trichostatin A (TSA) binding in HDAC8 from Homo sapiens, Echinococcus canadensis G7 and Mesocestoides corti. Cartoon
representations of (A) H. sapiens PDB 1T64 (HsaHDAC8; red) and model structures from (B) E. canadensis G7 (EcaHDAC8; blue) and M. corti (McoHDAC8; green). The
yellow sphere represents the catalytic ion zinc (Zn). TSA and residues involved in TSA binding are shown as sticks. Most residues involved in TSA binding in
HsaHDAC8 are conserved in EcaHDAC8 and McoHDAC8. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version
of this article.)
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McoHDAC8 (S20 and H286). Also, the replacement of L31 and M274
from HsaHDAC8 were previously reported in SmpHDAC8 (S18 and
H292) (Marek et al., 2013). We also found that the residues implicated
in the coordination to Zn2+ were conserved in HDAC8 from all ana-
lyzed species (Supplementary Fig. S2).
Furthermore, we identified particular structural characteristics in
EcaHDAC8 and McoHDAC8 (Fig. 5). In these proteins, the phenylala-
nine (F154) could adopt a particular conformation known as “flipped-
out” due to the surrounding residues. We showed that leucine (L31)
from HsaHDAC8 was replaced by a smaller serine residue behind the
phenylalanine (F154) in EcaHDAC8 (S20) and McoHDAC8 (S20). We
also showed the presence of the aromatic residues forming the “aro-
matic cage” that could interact with the phenylalanine (F154) in
EcaHDAC8 (Y23, F107, Y113, W143 and Y156) and McoHDAC8 (Y23,
F107, Y113, W143 and Y156). These characteristics were previously
identified in SmpHDAC8 (Marek et al., 2013). In this protein, leucine
(L31) from HsaHDAC8 was replaced by a serine residue (S18) and the
residues forming the “aromatic cage” (F21, F104, Y110, W140 and
Y153) were identified, as was previously described (Marek et al., 2013).
Finally, we analyzed the residues implicated in the binding of TSA
(Fig. 6). The available structure from HsaHDAC8-TSA is shown in
Fig. 6A. We showed that residues implicated in the binding of TSA were
highly conserved in EcaHDAC8 (Fig. 6B) and McoHDAC8 (Fig. 6C),
suggesting that the pan-HDAC inhibitor TSA could act as inhibitor of
EcaHDAC8 and McoHDAC8.
3.4. The pan-HDAC inhibitor “Trichostatin A″ decreases Mesocestoides
corti viability
In order to determine the relevance of HDACs in cestodes, we per-
formed viability and motility assays to determine the effect of the pan-
HDAC inhibitor TSA on M. corti TTy maintained in culture (Fig. 7). The
AlamarBlue assay showed that TSA produced a decrease of viability on
treated-TTy at 6 days compared to untreated-TTy (p < 0.0001 for
1 μM, 10 μM and 20 μM TSA) (Fig. 7A). No effect on treated-TTy was
observed at 3 days (data not shown). The motility assay showed that
TSA produced a decrease of relative motility indexes on treated-TTy at
6 days compared to untreated-TTy (p < 0.0001 for 1 μM, 10 μM and
20 μM TSA) (Fig. 7B). Visual inspections showed that TSA produced an
alteration of the tegument and loss of parasite morphology on treated-
Fig. 7. Effect of Trichostatin A (TSA) on viability
of Mesocestoides corti tetrathyridium (TTy) in
culture. (A) The AlamarBlue assay and (B) the mo-
tility assay by worm tracker device at 6 days of M.
corti TTy treatment. TTy were incubated in 200 μL of
culture medium with 1, 10 and 20 μM of TSA or the
vehicle (DMSO 1%). Three independent biological
replicates were used. Error bars represent the SD.
Praziquantel (PZQ) and ethanol 70% (EtOH 70%)
were used as positive controls. In all panels, asterisks
indicate those values showing differences with sta-
tistical significance compared to control according to
ANOVA tests (***, p < 0.001; ****, p < 0.0001).
Inverted optical microscope images of M. corti TTy
incubated with 40 μM TSA at (D) 3 and (F) 6 days or
M. corti TTy incubated with DMSO 1% at (C) 3 and
(D) 6 days. Scale bars represent 50 μm.
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TTy with 40 μM of TSA at 3 and 6 days (Fig. 7D and F). Also tegument
debris and presence of blebs were observed on treated-TTy. These
phenotypic alterations were not observed in untreated-TTy at 3 and 6
days (Fig. 7C and E).
3.5. TSA strongly inhibits protein deacetylation in Mesocestoides corti
We evaluated changes in the total amount of acetylated proteins of
M. corti TTy by Western Blot using both anti acetylated-histone H4
antibody and anti pan-acetylated-protein antibody (Fig. 8 and
Supplementary Fig. S3). We observed a band with a relative molecular
mass of ∼14 kDa consistent with the relative molecular mass of the
acetylated H4 histone in TSA treated-TTy at 3 and 6 days using anti
acetylated-histone H4 antibody (Fig. 8A and Supplementary Fig. S3A).
We observed two bands with a relative molecular mass of ∼14 kDa
consistent with the relative molecular mass of the acetylated histones
and an additional band with a relative molecular mass of ∼50 kDa in
TSA treated-TTy at 3 and 6 days using anti pan-acetylated-protein an-
tibody (Fig. 8A and Supplementary Fig. S3A, respectively). The relative
density of the bands observed in TSA treated-TTy at 3 or 6 days (Fig. 8B
and Supplementary Fig. S3B, respectively) was several times higher
than that of the control (1% DMSO) or the bands corresponding to PZQ
and ABZ treated-TTy, suggesting a specific effect of TSA.
4. Discussion
In this study we report the HDACs repertoire from several species of
cestode parasites. We identified between 6 and 7 zinc-dependent
HDACs in the genomes of species from Echinococcus, Taenia,
Mesocestoides and Hymenolepis genera, including the previously re-
ported HDAC1 from E. multilocularis (Koziol et al., 2014). Three of them
correspond to Class I HDACs and 3–4 to Class II HDACs. The number of
Class I and Class II HDACs genes is similar to those found in S. mansoni
genome, where 3 HDACs from Class I HDACs and 4 from Class II HDACs
were identified (Scholte et al., 2017). A reduced number of HDAC genes
are present in the analyzed cestodes with respect to Homo sapiens that
might reflect the lower complexity of these parasites. Only one member
of the subclass HDAC1/2 was found in all analyzed cestodes coin-
cidently with S. mansoni (Marek et al., 2015) in agreement with the idea
that HDAC1 duplication is specific to vertebrates (Brunmeir et al.,
2009).
Transcriptional expression levels of HDACs showed that all HDACs
here identified are expressed in several developmental stages of E.
granulosus s. s. G1 and E. multilocularis. The wide expression of Class I
and Class II HDACs suggests important roles for parasite biology and
survival in their hosts. Expression of the three Class I HDAC genes was
also reported in several developmental stages in S. mansoni (Oger et al.,
2008). In this parasite, SmpHDAC8 is expressed in all developmental
stages analyzed and is the most abundant Class I HDACs transcript in
several stages (Oger et al., 2008). However, in E. granulosus s. s. G1 and
E. multilocularis it does not seem to be the case. In E. granulosus s. s. G1,
EgrHDAC1 is the most abundant Class I HDACs transcript in all de-
velopmental stages. EgrHDAC8 is only expressed in adult and cyst wall
developmental stages, both stages which are able to produce onco-
spheres and protoscoleces, respectively, suggesting that EgrHDAC8
might have a role in E. granulosus s. s. G1 development. In E. multi-
locularis, EmuHDAC1 is the most abundant Class I HDACs transcript in
oncospheres and cyst wall developmental stages. EmuHDAC8 showed a
particularly high expression in activated oncospheres, compared to
oncospheres, suggesting a role for this protein in E. multilocularis de-
velopment. The different expression of HDAC8 in oncospheres from E.
granulosus s. s. G1 and E. multilocularis could be due to the fact that E.
granulosus s. s. G1 was sequenced by using Roche 454 (Zheng et al.,
2013), whereas E. multilocularis was sequenced by using Illumina GA
(Huang et al., 2016) which provides higher sequencing depth. Thus, the
transcriptional data shown may not be comparable between species.
Fig. 8. Hiperacetylation of Mesocestoides corti tetrathyridium (TTy) proteins by Trichostatin A (TSA). (A) M. corti TTy were treated with 20 or 40 μM TSA or
1% DMSO (control) for 3 days, followed by preparation of protein lysates and Western Blot analyses using anti acetylated-histone H4 and anti pan-acetylated-protein
antibodies. As negative controls, 20 μM praziquantel (PZQ) and albendazole (ABZ) were used. The panel below Western Blot represents the gel stained with
Coomassie Blue. (B) Densitometry analyses from western blots were performed and normalized with the total amount of proteins of the same sample observed by
Coomassie Blue staining. Results are expressed as the fold change in relative density compared to the control (1% DMSO), set to one. Error bars represent the SD.
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Proteins with higher sequence divergence with Homo sapiens or-
thologs are better candidates as selective drug targets. The analysis of
amino acid identity of HDAC catalytic domains showed that some of the
HDAC proteins such as HDAC8 and HDAC6 differ in more than 55%
with the human orthologs, suggesting that these differences could be
exploited pharmacologically. We focused on cestode HDAC8 since these
proteins show only 45–48% of identity with the H. sapiens HDAC8. Also,
HDAC8 is expressed in several development stages of genus
Echinococcus spp., especially in cyst wall developmental stage, the re-
levant stage for human disease. Furthermore, S. mansoni HDAC8 is re-
garded as a promising drug target for schistosomiasis, due to its specific
structural features which differentiate it from its human orthologs and
paralogs (Heimburg et al., 2016; Marek et al., 2013, 2015).
In this study we confirmed for the first time the complete nucleotide
sequences of HDAC8 from E. canadensis G7 and M. corti by cloning and
sequencing. We found, by homology modeling, that EcaHDAC8 and
McoHDAC8 adopt the canonical HDAC fold; suggesting that these en-
zymes might be active. Interestingly, we found some differences with
HsaHDAC8, including: i) insertions that extend external surface loops,
ii) replacement of methionine (M274) from HsaHDAC8 by histidine in
the cestodes HDAC8 proteins analyzed iii) replacement of leucine (L31)
from HsaHDAC8 by serine in the cestode HDAC8 proteins analyzed iiii)
the aromatic residues, forming the “aromatic cage“. These character-
istics found in EcaHDAC8 and McoHDAC8 were also reported in pre-
dicted HDAC8 sequences from E. granulosus s. s. G1, E. multilocularis, H.
microstoma and T. solium by homology modeling (Marek et al., 2013;
Melesina et al., 2015). Interestingly, the differences above mentioned
are also present in SmpHDAC8 and allowed the design of selective
SmHDAC8 inhibitors in S. mansoni (Heimburg et al., 2016). These se-
lective SmHDAC8 inhibitors might also be potential cestode HDAC8
inhibitors, and hence be novel potential drugs against Neglected Tro-
pical Diseases caused by cestodes.
The overall structural conservation of EcaHDAC8 and McoHDAC8
with HsaHDAC8, including residues involved in TSA binding, suggests
that the HDAC inhibitor TSA might inhibit HDAC from cestodes. This
encouraged us to determine whether TSA has an effect on parasite
viability. Here we showed that TSA decreased the viability of M. corti
TTy by means of two independent methods of viability determination.
Furthermore, alteration of the tegument and loss of parasite mor-
phology were observed on M. corti TTy after treatment with TSA and
other chemotherapeutic agents such as PZQ and ABZ. This result shows
that TSA produces phenotypic alterations on M. corti TTy also observed
with commonly used chemotherapeutic agents (Markoski et al., 2006).
In agreement with our results, a decrease of viability on juvenile forms
of S. mansoni was observed after incubation with TSA at comparable
concentrations and incubation times (Dubois et al., 2009).
In this study, we analyzed changes in the total amount of acetylated
M. corti proteins. We observed hyperacetylation of histone H4 and other
non-histonic proteins after treatment with TSA. These results suggest
that HDACs from M. corti are inhibited by the HDAC inhibitor TSA.
However, whether this is a direct or indirect effect is not known.
Moreover, hyperacetylation of M. corti proteins were observed at 6
days, in coincidence with a decrease of M. corti viability. Also, hyper-
acetylation of M. corti proteins were observed at shorter times (3 days),
suggesting that there is a delay on the TSA inhibitory effect on M. corti
viability. The presence of two bands with relative molecular masses
around ∼14 kDa, using anti pan-acetylated-protein antibody in M. corti
TTy after treatment with TSA, suggests that also other histones different
from histone H4, such as histone H2A or H3 from M. corti, were hy-
peracetylated as a consequence of the treatment. The relative molecular
mass of the bands observed is consistent with their identification of M.
corti histones H2A and H3. This assay clearly shows that TSA causes an
increase of protein acetylation, probably through HDAC inhibition,
suggesting that the function of HDACs is likely conserved in cestodes.
In conclusion, we showed the full repertoire of HDAC genes in
several members of the class Cestoda. We classified them as Class I
HDAC and Class II HDAC and analyzed their expression levels
throughout developmental stages of Echinococcus spp. Also, we con-
firmed for the first time the complete nucleotide sequences of HDAC8
from E. canadensis G7 and M. corti. We identified particular structural
features in EcaHDAC8 and McoHDAC8 homology models which dif-
ferentiate them from HsaHDAC8, suggesting that these proteins are
potential drug targets. We also showed that the pan-HDAC inhibitor
TSA decreases M. corti viability, alters its tegument and morphology
and produces hyperacetylation of its proteins. These results suggest that
HDAC from cestodes are functional and might play important roles on
M. corti survival and development. This report provides the basis for
further studies on cestodes HDAC activity and structure and also for
discovery of new HDAC inhibitors for the treatment of Neglected
Tropical Diseases caused by cestode parasites.
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